Viimane versioon :
08/05/2024
Vähiravimite   Oxaliplatin  
Süsteravim
Stabiilsus lahustes Stabiilsust mõjutavad tegurid Stabiilsust mõjutavad faktorid Sobimatus Manustamis viis Viited Pdf
   Keemiline struktuur  

Kaubanduslikud nimed erinevates maades   Kaubanduslikud nimed erinevates maades     

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Axiplatin Saksamaa
Bendaplatin Saksamaa
Bioezulen Brasiilia
Celdach Maroko
Crisapla Ecuador, Tšiili, Venetsueela
Crisatinox Türgi
Dabenzol Argentiina, Ecuador
Dacplat Argentiina
Eloxarin Ecuador
Eloxatin Ameerika ühendriigid, Araabia Ühendemiraadid, Austria, Belgia, Brasiilia, Egiptus, Hispaania, Iraan, Itaalia, Kolumbia, Luksemburg, Malaisia, Maroko, Mehhiko, Norra, Portugal, Rootsi, Rumeenia, Suurbritannia, Sveits, Tai, Tšiili, Türgi, Uus-Meremaa, Venetsueela
Eloxatine Maroko, Prantsusmaa, Sveits
Entia Kolumbia, Mehhiko
Euroxaliplatine Saksamaa
Glenoxal Maroko
Goxyral Argentiina, Ecuador
Kebir Argentiina, Maroko
Linoxa Türgi
Lisix Tšiili
Metaplatin Argentiina
Oliptino Argentiina
Onicol Maroko, Tšiili
Oxalibbs Brasiilia
Oxaliplan Saksamaa
Riboxatin Saksamaa
Viited   Süsteravim   Viited : Oxaliplatin  
Tüüp Avaldamine
1662 Ajaleht Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1950 Ajaleht Trissel LA, Yanping Z.
Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin and oxaliplatin during simulated Y-site administration.
J Oncol Pharm Practice 2004 ; 10: 191-195.
2207 Ajaleht André A, Cisternino S, Roy A.L, Chiadmi F, Schlatter J, Agranat P, Fain O, Fontan J.E.
Stability of oxaliplatin in infusion bags containing 5% dextrose injection.
Am J Health-Syst Pharm 2007 ; 64, 18: 1950-1954.
2239 Ajaleht Wang C, Zhang X, Liu HY.
Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry.
Chinese J New Drugs 2005 ; 14, 2: 189-191.
2253 Ajaleht Curis E, Provost K, Bouvet D, Nicolis I, Crauste-manciet S, Brossard D, B?nazeth S.
Carboplatin and oxaliplatin decomposition in chloride medium, monitored by XAS.
J Synchrotron Rad 2001 ; 8: 716-718.
2258 Labor Stability of oxaliplatin "Ebewe" lyophilisate after reconstitution.
Ebewe Pharma 2007
2259 Labor Stability of oxaliplatin "Ebewe" lyophilisate infusion solutions.
Ebewe Pharma 2007
2321 Ajaleht Junker A, Roy S, Desroches M.C, Moussay C, Berhoune M, Bellanger A, Fernandez C,Farinotti R.
Stability of Oxaliplatin Solution.
Ann Pharmacotherapy 2009 ; 43,2: 390-391.
2791 Ajaleht Mehta A.M,.Van den Hoven J.M, Rosing H,.Hillebrand M.J.X, Nuijen B,. Huitema A.D.R, Beijnen J.H,.Verwaal V.J.
Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.
Int J Pharm 2015 ; 479 : 23-27.
2883 Ajaleht Eiden C, Philibert L, Bekhtari K, Poujol S, Malosse F, Fr?d?ric Pinguet F.
Physicochemical stability of oxaliplatin in 5% dextrose injection stored in polyvinyl chloride, polyethylene, and polypropylene infusion bags.
Am J Health-Syst Pharm 2009 ; 66, 21: 1929-1933.
3369 Labor Levofolinate de sodium Medac - Résumé des caractéristiques du produits
MEDAC France 2011
3413 Ajaleht Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H.
Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex.
Pharm Res 2004 ; 21, 5: 891-894.
3602 Labor Mesna (Uromitexan®)- Summary of Product Characteristics
Baxter SAS 2013
3634 Labor Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit
Accord Healthcare 2011
3670 Ajaleht Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3706 Ajaleht Escudero-Ortiz V, Duart-Duart M.J, P?rez-Ruixo C, P?rez-Ruixo J.J, Valenzuela B.
Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia.
Farm Hosp 2014 ;38, 3:154-161
4004 Ajaleht Krämer I, Sarakbi I, Thiesen J, Mainz.
Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln.
Krankenhauspharmazie 2017 ;38,7:334?340.

  Mentions Légales